Venofer denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for venofer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Venofer as Duplicate Therapy

Venofer (iron sucrose injection) is an intravenous iron preparation used to treat iron-deficiency anemia, most commonly in patients with chronic kidney disease or other conditions that impair oral iron absorption. Cigna issues a duplicate-therapy denial when their records show another iron preparation — oral iron supplements, a different IV iron product, or another iron formulation — is already active on the patient's claim history. The insurer's system flags the combination as clinically redundant.

## Why This Denial Is Appealable

Duplicate-therapy flags are often based on pharmacy claims data that does not capture the clinical context: for example, oral iron may have been tried and failed, or a different IV iron product may have been discontinued before Venofer was prescribed. The prescriber's clinical rationale for selecting Venofer specifically — rather than another iron preparation — is the core of the appeal. Distinct pharmacokinetic properties, tolerability differences, and administration-setting requirements mean that two iron products are not automatically interchangeable, and clinical documentation of this distinction routinely reverses duplicate-therapy denials.

## Federal Appeal Framework

• Internal appeal: File within the deadline on the denial notice. Cigna must respond within 30 days (pre-service) or 60 days (post-service) for standard internal appeals.
• Expedited review: If clinical urgency warrants, request expedited processing; Cigna must respond within 72 hours.
• External review (ACA §2719 / ERISA §503): After a final adverse internal determination, request IRO external review within approximately 4 months. The IRO's decision is binding on Cigna.

## Documentation to Gather

• Medication reconciliation record: A complete, dated list of all iron preparations the patient has been prescribed, clearly showing which are active and which have been discontinued and why.
• Trial-and-failure documentation: Chart notes and lab trends showing inadequate response to, or intolerance of, any iron preparation Cigna's system considers a duplicate.
• Prescriber letter distinguishing Venofer: A clinical explanation of why Venofer (iron sucrose) is selected over the preparation Cigna identified, addressing tolerability, clinical setting, infusion requirements, or disease-specific factors.
• Diagnosis and lab trend documentation: Iron studies and anemia-related labs showing persistent or worsening iron deficiency despite the therapy Cigna flagged.

## Criteria-Mapping Structure

Retrieve Cigna's published coverage policy for intravenous iron preparations. For each criterion or exclusion cited in the denial, provide a specific chart reference or prescriber statement that addresses it directly. Demonstrate that the clinical circumstances distinguish Venofer from whatever therapy triggered the duplicate flag.